Q1 2025 · 13F-HR
BVF INC/ILholdings as filed
Filed 2025-05-15 · accession 0000921895-25-001528
$2.45B
Reported value
51
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $771.7M | 31.5% | 19,751,284 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $197.1M | 8.03% | 1,690,221 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $176.2M | 7.18% | 4,982,384 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $141.3M | 5.76% | 5,161,801 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $126.0M | 5.13% | 2,796,513 | Common | SHARED |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $124.5M | 5.08% | 2,575,015 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $97.4M | 3.97% | 8,827,712 | Common | SHARED |
| 98419J206 | XOMA | XOMA ROYALTY CORPORATION | $59.5M | 2.42% | 2,983,026 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $57.7M | 2.35% | 1,913,385 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $51.3M | 2.09% | 4,308,935 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $51.2M | 2.09% | 7,754,129 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $43.5M | 1.77% | 5,750,683 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $37.1M | 1.51% | 19,822,436 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $36.7M | 1.50% | 3,944,194 | Common | SHARED |
| 36315X101 | LKFT | GALAPAGOS NV | $36.5M | 1.49% | 1,454,422 | Common | SHARED |
| 15102K100 | CELC | CELCUITY INC | $35.0M | 1.43% | 3,466,000 | Common | SHARED |
| 92539P101 | — | VERVE THERAPEUTICS INC | $31.6M | 1.29% | 6,904,050 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $30.7M | 1.25% | 1,771,417 | Common | SHARED |
| 98401F105 | XNCR | XENCOR INC | $29.2M | 1.19% | 2,740,141 | Common | SHARED |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $26.3M | 1.07% | 5,660,132 | Common | SHARED |
| 81734D104 | SEPN | SEPTERNA INC | $25.5M | 1.04% | 4,396,124 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $21.3M | 0.87% | 6,293,282 | Common | SHARED |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $19.9M | 0.81% | 924,642 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $19.9M | 0.81% | 5,295,893 | Common | SHARED |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $19.5M | 0.79% | 696,555 | Common | SHARED |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $19.4M | 0.79% | 5,302,000 | Common | SHARED |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $18.4M | 0.75% | 3,075,000 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $14.7M | 0.60% | 4,561,289 | Common | SHARED |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $13.8M | 0.56% | 8,748,629 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $13.5M | 0.55% | 7,000,000 | Common | SHARED |
| 92337C203 | VSTM | VERASTEM INC | $12.7M | 0.52% | 2,100,468 | Common | SHARED |
| 75382E109 | — | RAPT THERAPEUTICS INC | $11.3M | 0.46% | 9,237,556 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $10.2M | 0.42% | 10,333,600 | Common | SHARED |
| 4525EP101 | VTLUSD | IMMUNIC INC | $9.7M | 0.40% | 8,902,972 | Common | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $8.3M | 0.34% | 1,036,679 | Common | SHARED |
| 88427A107 | — | THIRD HARMONIC BIO INC | $8.2M | 0.34% | 2,372,933 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $7.1M | 0.29% | 4,013,633 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $6.7M | 0.28% | 4,889,474 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $5.5M | 0.22% | 1,353,968 | Common | SHARED |
| 45175G108 | — | IKENA ONCOLOGY INC | $5.1M | 0.21% | 4,006,564 | Common | SHARED |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $4.6M | 0.19% | 594,282 | Common | SHARED |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $3.8M | 0.15% | 16,552,417 | Common | SHARED |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $3.3M | 0.14% | 5,228,461 | Common | SHARED |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $2.2M | 0.09% | 339,549 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $2.1M | 0.08% | 686,040 | Common | SHARED |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $2.0M | 0.08% | 9,544,262 | Common | SHARED |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $1.2M | 0.05% | 917,826 | Common | SHARED |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $1.2M | 0.05% | 59,065 | Common | SHARED |
| 690469101 | OVID | OVID THERAPEUTICS INC | $1.2M | 0.05% | 3,853,818 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $605,057 | 0.02% | 945,402 | Common | SHARED |
| H57830137 | — | NLS PHARMACEUTICS LTD | $221,261 | 0.01% | 143,676 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.